~~<i id='D5A7CDCFCB'><strike id='D5A7CDCFCB'><tt id='D5A7CDCFCB'><pre id='D5A7CDCFCB'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：Wikipedia 2025-10-01 19:09:09 Page View：4

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The biotech scorecard for Q4: 16 stock
Next article： How one medical school became remarkably diverse

leisure time

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

The stability of $0 premiums in Medicare Advantage

PabloMartinezMonsivais/APYou’rereadingthewebeditionofHealthCareInc.,STAT’sweeklynewsletterfollowingt

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Setback for rare diseases as Taysha Gene Therapies pulls back

AdobeIn2020,asbiotechstockssurgedamidthepandemic,astartupcalledTayshaGeneTherapiesraisedover$300mill